(1) We're living in the motorised middle ages | Martin Belam Read more “Driverless cars could represent the most fundamental change to transport since the invention of the internal combustion engine.
(2) Martin Belam, the digital product development consultant who worked with Coles to launch UsVsTh3m , is also working on Project Y.
(3) As my colleague Martin Belam has said , as long as you live you will never see a photograph of seven women signing legislation that defines and controls what men can do with their reproductive organs.
(4) We're living in the motorised middle ages | Martin Belam Read more But it’s hard to believe smart cars will ever completely kill old-fashioned human driving for the rest of us, any more than digital music did vinyl.
Blam
Definition:
Example Sentences:
(1) COP-BLAM III therapy was given to 18 patients with non-Hodgkin's lymphoma, and the therapeutic effects as well as adverse effects of the treatment were examined.
(2) COP-BLAM therapy, which has recently been reported to be useful in the treatment of malignant lymphoma, was performed on aged patients with non-Hodgkin's lymphoma, and the results and adverse effects of the treatment were evaluated.
(3) The course of disease in 61 consecutive patients with non-Hodgkin lymphoma of high grade malignancy, treated between 1979 and 1985 with either CHOP or COP-BLAM regimen, was analysed retrospectively.
(4) A full but short remission set in during a six-drug COP-BLAM treatment regimen.
(5) COP-BLAM III, an outgrowth of studies using infusional therapy, differed from COP-BLAM by using infusional bleomycin and vincristine alternated with bolus vincristine.
(6) By introducing TnblaM into bacterial cells and selecting ampicillin-resistant (ApR) colonies, the subset of isolates producing extracytoplasmic BlaM, and hence containing TnblaM inserted in genes encoding secreted proteins and cell envelope proteins, can be directly selected.
(7) COP-BLAM V employs four to six sequential cycles of infusional chemotherapy tailored to the rapidity of response.
(8) Elderly patients (aged greater than or equal to 65 years) with non-Hodgkin's lymphoma were treated either with CHOP or COP-BLAM therapy, and the effectiveness and reverse effects of COP-BLAM therapy were compared with those of CHOP therapy.
(9) Of 18 patients (median age; 68 years), who were treated with COP-BLAM therapy, 8 had of large lymphoma and 10 medium lymphomas in histopathological classification.
(10) Moreover, the ApR selection that is used with TnblaM can be fine-tuned to obtain blaM fusions to poorly or well-expressed genes.
(11) These regimens, COP-BLAM III, MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin), ProMACE-CytaBOM (ProMACE plus cytarabine, bleomycin, vincristine, methotrexate), and high-dose doxorubicin with cytarabine, have produced over 80% CRs and survival plateaus in excess of 60%.
(12) COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine), M-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone), and ProMACE-MOPP (prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, mechlorethamine, vincristine, procarbazine, prednisone) have produced CRs in excess of 70% and have demonstrated an increase in survival that has been associated with a concomitant increase in toxicity.
(13) The components of this system are the direct expression vector, pYZ4, and the mature beta-lactamase (BlaM) cassette plasmid, pYZ5, that can be used to generate translational fusions of BlaM to any synthesized membrane protein.
(14) Among 13 patients in advanced stage treated with COP-BLAM therapy, CR was achieved in 11 (84.6%).
(15) Preliminary results in patients with high-risk Hodgkin's disease suggest COP-BLAM V may be effective despite the shortened treatment time.
(16) Various seats and microphones cover the stage: this is a reading, not a stage adaptation; there will be no blood, just a lot of finger-guns and Tarantino yelling "blam-blam-blam!"
(17) Patients in partial remission (PR) or with less of a response to COP-BLAM were switched to IMV.
(18) The fusion protein conferred ampicillin resistance on individual host cells, indicating that the BlaM portion had been translocated to the bacterial periplasm, and that, by inference, the eukaryotic plasma-membrane protein can insert into the bacterial cytoplasmic membrane.
(19) After completion of three courses of COP-BLAM III therapy, which was started on June 7, a partial response was achieved.
(20) TnblaM is a spectinomycin-resistant derivative of Tn5 with an unexpressed open reading frame encoding mature beta-lactamase (BlaM) at its left end.